Complete remission after isolation of patients with recurrent ovarian cancer viable again cytoreductive surgery

Recurrent ovarian cancer may reoperation Health, will be right recurrent ovarian cancer surgery and chemotherapy again whether there has been significant controversy. Fourth Militar...

Laparoscopic exploration of two safety accurate ovarian cancer Laparoscopic surgery for ovarian cancer patients with secondary exploration (2 exploration) is a safe and accurate method, this low rate of ...

Denmark Gronloud such report, as paclitaxel plus platinum chemotherapy after complete remission in patients with ovarian cancer, if recurrence of a solitary lesion again cytoreductive surgery may improve survival. (Eur J Surg Oncol 2005,31:67)

In the retrospective study selected criteria: 1 Guide to the residual initial stage operation and confirmed by histological examination of epithelial ovarian cancer; (2) complete remission after first-line treatment; 3. Imaging confirmed pots peritoneal metastasis; (4) Surgical resection of lesions for the purpose.

In 572 cases, 38 cases qualify. 16 patients with completely resected tumors (complete resection rate was 42%), partial resection in 9 cases, 13 cases due to tumor near important organs (five cases) or large tumor surgery and can not complete resection (n = 7) or more of the dense adhesions (1) not accepted by cell eliminate operation.

Completely isolated lesions and surgical resection independently correlated (P = 0.009). Complete resection surgery compared to those of the resection or removal of survival was significantly longer period, the median survival time was 51.8 months and 19.9 months (P = 0.009).

Patients with residual tumor and survival independently correlated (P = 0.02), but if the number of tumor recurrence at the same time multivariate analysis, residual tumor was not significantly correlated with survival.

Researchers believe that it is the right choice of recurrent ovarian cancer patients again cytoreductive surgery to remove the tumor completely, can improve survival. However, the biological behavior of tumors and other factors relevant to the survival also play a very important role. The study not yet come to a decisive conclusion may be less concerned with the size of the sample, the greater the need for research.

Experience with ovarian cancer Treatment of ovarian cancer is still surgery and chemotherapy, although postoperative adjuvant systemic chemotherapy has been the effect cer...

Recurrent ovarian cancer chemotherapy new method - conventional chemotherapy drug efficacy forecast molecular targeted chemotherapy Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates gene...

Previous accept carboplatin multidrug chemotherapy in patients with recurrent ovarian cancer Carboplatin and Paclitaxel weekly therapy is safe and effective Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplati...

Conventional treatment The choice of ovarian cancer surgery, chemotherapy and radiotherapy. But because of its pathological type complex, qualitative, without a di...

How to reduce the recurrence of ovarian cancer (1). Complete removal of lesions in ovarian cancer surgery should be the primary tumor resection can see pots and peritoneal metastasis, or...

Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects Foreign Medical Obstetrics and Gynecology...

Advanced ovarian cancer patients quality of life

Diagnostic Classification